Themenstarter
- Beitritt
- 16.08.10
- Beiträge
- 210
FDA will be planning a series of activities focused on drug development to treat the symptoms of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS) in order to explore:
The burden of disease that impacts the quality of life for ME and CFS patients;
The quantitative outcome measures or endpoints that determine if disease symptoms improve with intervention; and
How drug efficacy should be clinically tested based on these endpoints or measurements.
Please send correspondence regarding ME and CFS to [email protected].[...]
Quelle: Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS)
The burden of disease that impacts the quality of life for ME and CFS patients;
The quantitative outcome measures or endpoints that determine if disease symptoms improve with intervention; and
How drug efficacy should be clinically tested based on these endpoints or measurements.
Please send correspondence regarding ME and CFS to [email protected].[...]
Quelle: Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS)
Zuletzt bearbeitet von einem Moderator:
